News

Galvany Pharma will be exhibiting at Current Issues in Palliative Care 2024. Taking place in London on 25th April this event brings together physicians, nurses and other healthcare professionals working within the areas of oncology, pain, dementia and palliative medicine.

Galvany Pharma launches Levorol 6.25mg tablets

Galvany Pharma will attend euroPLX 84 in Lisbon, Portugal on 27th and 27th February 2024

Galvany Pharma launches FENAPIN (caffeine citrate) 20 mg/ml Solution for Infusion

Galvany Pharma is pleased to have completed the NHS Evergreen Sustainable Supplier Assessment. The Assessment is a self-assessment and reporting tool supporting us to understand our alignment with NHS sustainability priorities and identify those areas in which we need to accelerate progress. The Evergreen Assessment is one of several NHS initiatives designed to support its net zero and wider sustainability objectives. We are delighted to be supporting the NHS to achieve their net zero and sustainability ambitions, including those set out in the NHS Net Zero Supplier Roadmap.

Galvany Pharma will attend CPhI Barcelona to meet with existing and potential new partners to further our development pipeline. Please contact us to arrange any meetings to discuss co-developments, contract development and licensing deals.

Galvany Pharma is proud to sponsor the St Clare Hospice Palliative Care Conference that will take place on Wednesday 27th September 2023. The theme of the conference is ‘Placing the person at the centre of their care’.

Galvany Pharma launches LEVOROL (levomepromazine HCl) 5mg/ml Oral Solution

Galvany Pharma will be exhibiting at the Palliative Care Congress from 16th to 17th March 2023 at the Edinburgh International Conference Centre (EICC). Please contact us for any further information.

Galvany Pharma will attend euroPLX in Athens on November 28th and 29th.

Galvany Pharma will attend CPhI Frankfurt to meet with existing and potential new partners to further our development pipeline. Please contact us to arrange any meetings to discuss co-developments, contract development and licensing deals.

The sale of Synchrony Pharma excluded over 20 products in development. The same founders and management team are excited to commercialise this pipe-line under the new company, Galvany Pharma, which will realise significant patient value.